#NEWS: The U.S. FDA has approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. Learn more here: t.co/xo3SRuiBaH #JNJOncology t.co/Yy3AVmQBvE